Top US Health Official Quietly Visits Israel Amid Vaccine Patent Data Dispute; Who Really Profits From the Silence?
Sources close to the delegation confirm the official met with pharmaceutical executives and defense contractors behind closed doors, sparking questions about the true agenda behind the publicly stated 'humanitarian aid' mission. While mainstream outlets frame the visit as standard diplomatic protocol, internal documents leaked from a Tel Aviv-based think tank suggest the discussions centered on extending patent protections for a new mRNA treatment, a move that critics say prioritizes corporate monopoly over global health equity. The official's office has declined to comment on the specific meetings, but skeptics note that the timing coincides with a major Supreme Court battle over generic drug competition back in Washington.